Dianthus Therapeutics, Inc. (DNTH) – What Are Brokerages Saying About This Stock?

Posted by Brian Himes on Oct 15th, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $129.83.

A number of brokerages have recently weighed in on DNTH. Citigroup started coverage on shares of Dianthus Therapeutics in a research note on Friday, September 4th. They set a “buy” rating and a $156.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Dianthus Therapeutics in a research note on Friday, September 11th. They issued an “overweight” rating and a $135.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Truist Financial raised their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, HC Wainwright boosted their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th.

Read Our Latest Report on DNTH

Dianthus Therapeutics Trading Down 3.6%

Shares of NASDAQ DNTH opened at $74.76 on Thursday. The stock has a market cap of $4.10 billion, a price-to-earnings ratio of -18.01 and a beta of 1.35. Dianthus Therapeutics has a 52 week low of $32.22 and a 52 week high of $117.88. The company’s 50-day moving average price is $100.75 and its 200 day moving average price is $94.49.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, research analysts expect that Dianthus Therapeutics will post -3.81 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Adam M. Veness sold 16,167 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the transaction, the senior vice president owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. This represents a 80.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Simrat Randhawa sold 23,124 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. This trade represents a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 242,429 shares of company stock worth $26,118,913 in the last 90 days. 3.02% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Dianthus Therapeutics during the second quarter worth approximately $401,990,000. Wellington Management Group LLP boosted its holdings in shares of Dianthus Therapeutics by 24.4% in the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after purchasing an additional 634,099 shares during the last quarter. Polar Capital Holdings Plc boosted its holdings in shares of Dianthus Therapeutics by 34.3% in the 4th quarter. Polar Capital Holdings Plc now owns 1,004,728 shares of the company’s stock valued at $41,405,000 after purchasing an additional 256,725 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at $40,713,000. Finally, Spruce Street Capital LP grew its stake in shares of Dianthus Therapeutics by 25.5% during the 1st quarter. Spruce Street Capital LP now owns 373,274 shares of the company’s stock valued at $31,325,000 after buying an additional 75,837 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.